Skip to main content

Neurocrine Biosciences, Inc.

corporate_fare Company Profile

Neurocrine Biosciences, Inc.

NBIX·NASDAQ·Life Sciences·CIK 0000914475

Neurocrine Biosciences is a biopharmaceutical company focused on neuroscience, dedicated to discovering, developing, and commercializing treatments for neurological, psychiatric, endocrine, and immunological disorders. The company's product portfolio includes U.S. Food and Drug Administration (FDA) approved treatments for tardive dyskinesia (TD), chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH), and endometriosis and uterine fibroids, the latter in collaboration with AbbVie Inc. Neurocrine Biosciences launched INGREZZA (valbenazine) in the U.S. in May 2017 for TD and in August 2023 for chorea associated with Huntington's disease. The company also launched CRENESSITY (crinecerfont) in the U.S. in December 2024 for CAH. The company estimates that TD affects approximately 800,000 people in the U.S., approximately 90% of the 40,000 people in the U.S. affected by Huntington's disease will develop chorea, and CAH affects at least 20,000 people in the U.S. INGREZZA net product sales were $2.51 billion for 2025, $2.31 billion for 2024, and $1.84 billion for 2023, representing a significant portion of total net product sales in each of these years. CRENESSITY net product sales were $301.2 million for 2025. The company's commercial products include treatments for Tardive Dyskinesia in the U.S., Japan, and select Asian markets; Chorea Associated with Huntington's Disease; Classic Congenital Adrenal Hyperplasia in the U.S.; and Endometriosis and Uterine Fibroids in the U.S. The company also has a diversified portfolio of multiple compounds in mid- to late-phase development and an expanding early-phase pipeline.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for NBIX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-03, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for NBIX spans 10-Q, 8-K, DEFA14A, DEF 14A.

Recent high-impact activity:

  • Neurocrine Jumps 15% on Third Straight Double Beat and Second Ingrezza Guidance Hike
  • Neurocrine Posts $3.29 Q3 Adjusted EPS as Revenue Jumps 41%
  • Neurocrine 10-Q: Q3 Revenue $1.12B, Net Income $206.5M; New VYKAT XR Generic Suit Filed
  • Neurocrine Q3 Revenue Tops $1.1B, INGREZZA Guidance Raised to $2.9-$2.925B
  • FDA Clears Phase 2 Trial for Neurocrine's Alzheimer's Drug NBI-1117567

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$2.86B
Net Income
$478.6M
Diluted EPS
$4.67
Op. Cash Flow
$782.7M
Free Cash Flow
$748.7M
Gross Profit
$2.81B
Operating Income
$619.1M
Cash & Equivalents
$713M
Debt / Equity
0.00×
Net Margin
16.7%
Shares Outstanding
100.1M sh
Source: 10-K · filed 2026-02-11 · accession 0000914475-26-000007

Short Interest & Short Volume

5.40 days to cover

FINRA reported short interest of 5,900,825 shares in NBIX as of the October 30, 2026 settlement, a 8.5% decrease from the prior period — about 5.4 days to cover at its recent average daily volume. On November 19, 2026, 61.7% of NBIX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)5,900,825 shares as of October 30, 2026
Change vs prior period▼ 8.5%
Days to cover5.40 at avg daily volume of 1,093,287
Daily short volume (FINRA facilities)61.7% of 529,644 shares on November 19, 2026
5-day average short volume53.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with N →
$151.4 -3.32% today
52-week range · as of 2026-11-02 $122.14 – $186.12
Market cap
$15.33B
Volume
1.1M (0.8× avg)
3-mo avg 1.4M
Live data · 2026-11-20 20:48 UTC · Market open

show_chartPrice Chart

Loading chart...

feed NBIX - Latest Insights

NBIX
Nov 03, 2026, 2:36 PM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $168.29
Real-time Price: $151.40 info
Change: -$16.89 (-10%) info
Market Cap: $15.328B info
NBIX
Nov 02, 2026, 4:50 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $157.48
Real-time Price: $151.40 info
Change: -$6.08 (-4%) info
Market Cap: $15.328B info
NBIX
Nov 02, 2026, 4:14 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $146.96
Real-time Price: $151.40 info
Change: +$4.44 (+3%) info
Market Cap: $15.328B info
NBIX
Nov 02, 2026, 4:11 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $145.35
Real-time Price: $151.40 info
Change: +$6.05 (+4%) info
Market Cap: $15.328B info
NBIX
Aug 26, 2026, 3:33 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $153.37
Real-time Price: $151.40 info
Change: -$1.97 (-1%) info
Market Cap: $15.328B info
NBIX
Aug 03, 2026, 7:33 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $167.40
Real-time Price: $151.40 info
Change: -$16.00 (-10%) info
Market Cap: $15.328B info
NBIX
Jul 30, 2026, 9:22 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $188.65
Real-time Price: $151.40 info
Change: -$37.25 (-20%) info
Market Cap: $15.328B info
NBIX
Jul 30, 2026, 4:12 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $185.50
Real-time Price: $151.40 info
Change: -$34.10 (-18%) info
Market Cap: $15.328B info
NBIX
Jul 30, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $190.75
Real-time Price: $151.40 info
Change: -$39.35 (-21%) info
Market Cap: $15.328B info
NBIX
May 28, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $156.39
Real-time Price: $151.40 info
Change: -$4.99 (-3%) info
Market Cap: $15.328B info
NBIX
May 19, 2026, 3:14 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $157.21
Real-time Price: $151.40 info
Change: -$5.81 (-4%) info
Market Cap: $15.328B info
NBIX
May 18, 2026, 9:04 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $158.42
Real-time Price: $151.40 info
Change: -$7.02 (-4%) info
Market Cap: $15.328B info
NBIX
May 18, 2026, 8:46 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $158.42
Real-time Price: $151.40 info
Change: -$7.02 (-4%) info
Market Cap: $15.328B info
NBIX
May 05, 2026, 4:03 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $143.48
Real-time Price: $151.40 info
Change: +$7.92 (+6%) info
Market Cap: $15.328B info
NBIX
May 05, 2026, 4:02 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $145.52
Real-time Price: $151.40 info
Change: +$5.88 (+4%) info
Market Cap: $15.328B info
NBIX
May 05, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $139.08
Real-time Price: $151.40 info
Change: +$12.31 (+9%) info
Market Cap: $15.328B info
NBIX
Apr 15, 2026, 4:17 PM EDT
Filing Type: DEFA14A
Importance Score:
8
Price at Filing: $131.44
Real-time Price: $151.40 info
Change: +$19.96 (+15%) info
Market Cap: $15.328B info
NBIX
Apr 15, 2026, 4:15 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $131.44
Real-time Price: $151.40 info
Change: +$19.96 (+15%) info
Market Cap: $15.328B info
NBIX
Apr 06, 2026, 7:35 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $128.99
Real-time Price: $151.40 info
Change: +$22.41 (+17%) info
Market Cap: $15.328B info
NBIX
Apr 06, 2026, 5:45 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $131.00
Real-time Price: $151.40 info
Change: +$20.40 (+16%) info
Market Cap: $15.328B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets